IVAC Consortium wins BMBF grant to develop individualized cancer vaccine

Public-private partnership will begin preclinical testing of melanoma immunotherapy based on individual tumor mutations

Mainz, February 13, 2012 – The German Ministry for Education and Research (BMBF) has granted 1.2 Mio EUR over 3 years to the Consortium of Individualized Vaccines for Cancer (IVAC), a public-private partnership that pursues the development, production, clinical testing and commercialization of RNA based individualized cancer vaccines for treatment of malignant melanoma, a severe form of skin cancer. The grant is being awarded as a result of the ministry’s call for „Innovative therapeutic processes on a molecular or cellular basis“.

Click here for more information